Silence unveils more PhI data for siRNA drug in new cardiovascular race targeting Lp(a)

Si­lence Ther­a­peu­tics’ siR­NA as­set showed hints of ef­fi­ca­cy in car­dio­vas­cu­lar dis­ease pa­tients en­rolled in a Phase I tri­al amid re­cent read­outs from pipeline ri­vals backed by Big Phar­ma com­pa­nies.

The biotech’s drug, zer­lasir­an, is de­signed to low­er the body’s pro­duc­tion of lipopro­tein(a), or Lp(a), which is con­sid­ered a ge­net­ic risk fac­tor for car­dio­vas­cu­lar dis­ease.

The Phase I APOL­LO tri­al stud­ied zer­lasir­an in 36 peo­ple with sta­ble ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease (AS­CVD) and base­line Lp(a) lev­els of at least 150 nmol/L. In the place­bo-con­trolled por­tion, three dif­fer­ent dos­es of zer­lasir­an were ad­min­is­tered to pa­tients twice at dif­fer­ent in­ter­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.